Kornimate/medical-research-clean huggingface dataset:
ready, set, go! a physical fitness intervention for children with mobility challenges

Conditions: Cerebral Palsy; Myelomeningocele; Arthrogryposis; Motor Skills Disorders; Gross Motor Development Delay

Summary: barriers to keeping and maintaining fitness as a young person with a disability exist across many domains of access to community locations such as fitness centers, so looking outside of these establishments may be necessary to advance fitness. this study is aimed at piloting a program that would address some of these barriers by hosting a modified after school running program with an underserved population in an accessible way. there is a second option to participate outside of school.


Eligibility criteria:
inclusion criteria: * a medical diagnosis (for example, cerebral palsy) that causes them mobility limitations exclusion criteria: * concurrent medical condition that would make exercise unsafe, * are unable to follow simple commands * have behaviors that would potentially compromise safety of fellow runners or caregivers
sleep hygiene intervention on undergraduate students' sleep and stress

Conditions: Stress, Emotional; Sleep Disturbance

Summary: poor sleep is common among college students and likely contributes to stress. the investigators developed a brief, remotely-delivered intervention and tested whether it improves sleep hygiene and reduced sleep disturbance and stress among undergraduates.

poor sleep is common among college students and likely contributes to stress. the investigators developed a brief, remotely-delivered sleep hygiene intervention, which is delivered via the internet, and tested in a randomized controlled trial, whether it improves sleep hygiene and reduced sleep disturbance and stress in a sample of undergraduates who report wanting to improve their sleep. this study compares the novel sleep hygiene intervention to an active, matched control condition--sleep education. baseline and 2-week follow-up questionnaires assess sleep hygiene, sleep disturbance, and stress. ancovas will compare conditions at follow-up, and mediation tests will explore whether the intervention reduced stress through improved sleep.

Eligibility criteria:
inclusion criteria: * undergraduate students at wayne state university * self-reported desire to improve their sleep exclusion criteria: * graduate students / professional students
myocardial infarction in the elderly

Conditions: Myocardial Infarction (MI)

Summary: an observational registry study of patients aged 75 years and older with an established diagnosis of myocardial infarction, initiated in 2020, with an assessment of clinical, instrumental, demographic and prognostic data. statistical analysis was performed using the stattech v. 4.5.0 program (developer - stattech llc, russia). differences were considered statistically significant at p \<0.05.


Eligibility criteria:
inclusion criteria: - age 75 years and older, presence of an established diagnosis of myocardial infarction at the time of hospitalization. exclusion criteria: -
assessment of pink esthetic score after using two papilla reconstruction exposure techniques versus mid-crestal sulcular incision in second stage implant surgery: a randomized controlled clinical trail

Conditions: Papilla Reconstruction

Summary: the purpose of this randomized clinical trial is to assess the pink esthetic score with three different techniques in second-stage implant surgery.


Eligibility criteria:
inclusion criteria: 1. patients who already received implants in the anterior and premolar region 2. all implants were placed 4 months prior to uncovering in the mandible and 6 months prior to uncovering in the maxilla. 3. patients with good oral hygiene 4. medically free patients 5. adequate keratinized tissue exclusion criteria: 1. acute infection 2. occlusal trauma 3. smokers 4. pregnancy and lactation 5. severe gag reflex
effect of tamsulosin on pe compared with paroxetine hydrochloride

Conditions: Premature Ejaculation

Summary: a study to compare the effect of tamsulosin versus the effect of paroxetine hydrochloride and the effect of combination of them on pe.

premature ejaculation is considered the most common male sexual disorder. affecting approximately 4-39 % of men in general community. in 2008, the international society for sexual medicine defined premature ejaculation as a male sexual dysfunction that is characterized by ejaculation that always or nearly always occurs within or before 1 minute of vaginal penetration. moreover it is associated with presence of distress, frustration, bother, negative personal consequences, depression and the avoidance of sexual intimacy. many etiological theories have been included in the pathogenesis of premature ejaculation: neurobiological, psychological, environmental and endocrine factors. so a lot of therapeutic modalities, such as behavioral therapy, selective serotonin reuptake inhibitors (ssris), adrenergic alpha 1 antagonists, local anesthetic creams, clomipramine, phosphodiesterase type 5 inhibitors and centrally acting analgesics have been used for the treatment of premature ejaculation. previous studies reported that tamsulosin which is alpha blocker agent used as primary therapeutic agent for bph is effective in the improvement of sexual function. however studies on the effect of tamsulosin on ejaculation reported that tamsulosin had inhibitory effect in the emission phase of ejaculation including decreased ejaculatory volume. so inhibitory effect of tamsulosin on ejaculation may be beneficial to patients suffering from premature ejaculation. historically, pe was considered psychological problem and was treated by behavioral treatment and psychotherapy but there is pharmacological studies increase the evidence that pe may be related to decreased serotonergic neurotransmission. so selective serotonin reuptake inhibitors (ssris ) such as : paroxetine, fluoxetine, dapoxetine, and sertraline are among the recommended pharmacological treatments for treating pe. but there is no universal agreement on the type, the dose and administration protocol. so a study is needed to compare the value of combination therapy of both tamsulosin and paroxetine with the value of single therapy of either of them and consider intravaginal ejaculatory latency time (ielt) and ejaculatory control ability of patients after using tamsulosin and paroxetine.

Eligibility criteria:
inclusion criteria: * married, sexually active patients with pe will be included with ages ranging from 20 to 60 years. exclusion criteria: * patients suffering from erectile dysfunction, dm, htn, neurological disorders and psychological disorders.
balanced growth: the involvement of the vestibular system in a child's cognitive and motor development

Conditions: Vestibular Disorder; Neurodevelopmental Disorders

Summary: when a vestibular dysfunction occurs at birth or in early stages of life, one might expect that this may have an enormous impact on a child's development. it is known that a severe congenital or early acquired vestibular deficit in children results in delayed psychomotor milestones. later in life, children with a vestibular dysfunction may have difficulties with several balance tasks and additional cognitive, motor and/or psychosocial performances. while a few authors have suggested that there is indeed an influence of a vestibular dysfunction upon these different developmental domains (cognitive, motor, educational and psychosocial development), which can be supported by findings in clinical practice as well, literature concerning this topic remains fairly limited. on the other hand, several studies have shown that children with known difficulties in motor and/or cognitive functions have more difficulties in vestibular performances in comparison with their unaffected peers. although more frequently discussed, the literature on this population is rather scarce too. therefore, the current project aims to investigate the relationship with and the involvement of the vestibular system in the motor and cognitive development of school-aged children.

general goals 1. developing and standardizing a sensitive and specific test protocol for the detection of vestibular, cognitive and/or motor dysfunctions in school-aged children. 2. investigate the relationship with and the involvement of the vestibular system in the motor and cognitive development of typically developing school-aged children. 3. investigating whether a vestibular dysfunction (with/without an additional auditory disease) has an impact on motor and/or cognitive performances in school-aged children. 4. investigating if in children with a known neurodevelopmental disorder an (additional) underlying vestibular dysfunction can be identified.

Eligibility criteria:
for typically developing children exclusion criteria: * having a (permanent) hearing loss * having a (permanent) vestibular loss * having a motor dysfunction * iq \< 70 for vestibular-impaired children inclusion criteria: * recently (\< 6 months) tested at the ghent university hospital * diagnosed with a vestibular impairment (= alteration on at least one of the vestibular function tests: caloric, rotatory chair, vhit, cvemp and/or ovemp test) for neurodevelopmental group inclusion criteria: • diagnosed by a (neuro)psychiatric team with autism spectrum disorder, attention deficit/hyperactivitiy disorder and/or developmental coordination disorder
enhanced function and quality of life following 5 months of exercise therapy for patients with rotator cuff tears

Conditions: Full Thickness Rotator Cuff Tear

Summary: this study aims to evaluate the effect of 5 months of exercise therapy for patients with irreparable rotator cuff tears.

all included patients will receive exercise therapy consisting of two exercises focusing on strengthening m. deltoideus anterior and m. teres minor.

Eligibility criteria:
inclusion criteria: * symptoms of rotator cuff rupture for at least three months with rupture of minimum musculus supraspinatus and musculus infraspinatus visualized by ultrasonography or arthroscopy * no neurological conditions which could affect muscle strength or activity * able to read and understand danish * both patients with and without a history of shoulder trauma were included exclusion criteria: * former rotator cuff surgery * history of shoulder fracture or inflammatory conditions in the shoulder * significant osteoarthritic changes on antero-posterior and/or lateral (outlet view) radiographs
a study of adh300004 in surgically resected primary or metastatic colorectal cancer and liver biopsy, or planned hepatic resection

Conditions: Neoplasms

Summary: 5 fluorouracil (5 fu), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (dpd). adh300004 blocks dpd. this study will examine the kinetics of inhibition and recovery of the metabolic pathways for fluoropyrimidines in subjects who receive a single oral dose of adh300004, and may allow optimization of oral 5 fu dosing to subjects in future studies.


Eligibility criteria:
inclusion criteria: * signed written informed consent * \> or = 19 years of age * patients with histologically confirmed: * primary or metastatic (known or suspected) colorectal carcinoma requiring planned surgical resection with hepatic biopsy and systemic chemotherapy , or * primary or metastatic neoplastic disease within the liver from any origin requiring planned surgical resection and systemic chemotherapy * adequate performance status and organ function, as evidenced by hematological and biochemical blood testing exclusion criteria: * lack of known or suspected metastatic disease in the liver * known dpd deficiency * severe infection * inability to take oral medication * the need for treatment with any fluoropyrimidine within 8 weeks of any adh300004 dose * stroke, major surgery, or other major tissue injury within 30 days before study entry

Keywords: cancer; tumors; neoplasms; anticarcinogenic agents; antineoplastic agents; dihydrouracil dehydrogenase (nadp); colorectal carcinoma; liver cancer
alinity m hr hpv specimen collection study from women undergoing routine cervical cancer screening

Conditions: Human Papillomavirus

Summary: a prospective multicenter interventional study will be conducted to enroll women undergoing routine cervical cancer screening to collect cervical liquid-based cytology (lbc) specimen(s). for all subjects, two cervical specimens will be collected, and one placed into hologic thinprep pap test collection kit with preservcyt solution (also referred to as thinprep specimen) and the other into bd surepath liquid-based pap test (also referred to as surepath specimen). cytology and hr hpv results will be generated and utilized to determine need for subject referral to colposcopy. collection of an endocervical curettage (ecc) specimen, and biopsy(ies) if applicable, from women who are referred to colposcopy as a follow up will be conducted according to a standardized protocol. disease status for each subject will be determined based on cytology, hpv test results, and/or consensus histology review of cervical biopsy specimens.


Eligibility criteria:
inclusion criteria: women is eligible if she meets the following: * is 25 years of age or older * is attending a participating clinic for routine cervical cancer screening following screening guidelines * has an intact cervix * is willing and able to provide documented informed consent * is willing and able to undergo colposcopy, biopsy, and endocervical curettage (ecc) within 12 weeks (≤ 84 days) from the baseline visit, if required * is willing and able to allow collection of two cervical cytology specimens exclusion criteria: a women is ineligible for the study if she meets any of the following criteria: * is pregnant at the time of visit or plans to become pregnant within the following 12 weeks * has any known medical condition that, in the opinion of the investigator, would result in increased risk of bleeding at biopsy * has a known history of excisional or ablative therapy (e.g., leep, cone biopsy, cervical laser surgery, or cryotherapy) to the cervix in the last 12 months prior to the baseline visit * had a cervical cytology specimen collected within the last 4 months * is currently participating in any diagnostic trial for cervical cancer * had a complete or partial hysterectomy, either supra cervical or involving removal of the cervix * is currently participating or planning to participate in any clinical trial for hpv treatment (for the duration of this study) * previous participation in this study

Keywords: hpv virus cervical cancer oncology screening tissue collection biopsy
the purpose of this study is to evaluate the safety and efficacy of human th-sc01 cell injection in the treatment of complex perianal fistula

Conditions: Complex Perianal Fistulas

Summary: the purpose of this study is to evaluate the safety and efficacy of human th-sc01 cell injection for the treatment of complex perianal fistulas

this study is a phase ⅰ/ⅱ study, phase 1 was the dose increment phase, and phase 2 was the expansion phase

Eligibility criteria:
inclusion criteria: 1. signed informed consent. 2. subjects aged between 18 and 70, both male and female. 3. the subject was clinically diagnosed as complex anal fistula. the diagnostic criteria for complex anal fistula were adopted by the 2016 american association of colorectal surgeons guidelines for the treatment of perianal abscess, anal fistula and rectovaginal fistula. 4. the subjects had received conventional treatment for anal fistulas 5. all subjects and their partners were not planning to have a child from screening to the end of the trial and agreed to use effective non-drug contraception during the trial. exclusion criteria: 1. subjects with anal fistula in the acute infection period. 2. subjects with abscess or collections \>2 cm. 3. subjects with abnormal laboratory results: liver function: total bilirubin \>=1.5 × uln, and aspartate aminotransferase (ast) and alanine aminotransferase (alt) \>=2 × uln; renal function: creatinine clearance below 60 ml/minute calculated using cockcroft-gault formula or by serum creatinine \>=1.5 × upper limit of normal (uln). 4. subjects with malignant tumors or a history of malignant tumors. 5. subjects with severe, progressive, uncontrolled hepatic, hematological, gastrointestinal (except crohn's disease), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases. 6. serum virology test (hbeag, hcv antibody, hiv antibody, treponema pallidum antibody) positive. 7. subjects allergic to gentamicin sulfate, anesthetics or contrast media. 8. subjects allergic to mri contrast. 9. subjects who has major surgery or severe trauma within 6 months prior to the screening period. 10. subjects who has received any investigational drug within 3 months prior to the screening. 11. subjects deemed inappropriate by the investigator to participate in this clinical trial. 12. the female participant who is pregnant, or is lactating.
quality of life in chinese postmenopausal hr(+) early breast cancer (ebc) patients during adjuvant aromatase inhibitors(ais) treatment

Conditions: Breast Cancer

Summary: the purpose of the study is to evaluate quality of life (qol) in postmenopausal hr (+) ebc patients during adjuvant ais treatment in terms of: the change of the trial outcome index (toi) of the fact-b questionnaire from baseline to 24 months. this study will recruit approximately 500 patients from 21 sites in china. the patients should be postmenopausal hr (+) ebc patients who have already start adjuvant ais treatment but within 7 days.


Eligibility criteria:
inclusion criteria: * postmenopausal women ≤ 70 years old, with histologically proven hr (+) early breast cancer. * undergoing upfront ais adjuvant treatment within 7 days. exclusion criteria: * patients who disagree to participate this study * patients who, for whatever reason (eg, confusion, infirmity), are unlikely to comply with trial requirements. * the ais have not been approved by sfda for the indication of upfront adjuvant endocrine therapy in early breast cancer.

Keywords: quality of life postmenopausal hr(+) early breast cancer adjuvant ai treatment quality of life in chinese postmenopausal hr(+) ebc patients during adjuvant aromatase inhibitors(ais) treatment
phase i dose escalation study for vip152 in patients with advanced cancer

Conditions: Neoplasms

Summary: determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (mtd) and recommended phase 2 dose (rp2d) of vip152 (bay 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin's lymphoma (nhl).

part 2 vip152 monotherapy (global). part 3 dose escalation with vip152 in combination with pembrolizumab (us only). part 4 dose expansion with vip152 in combination with pembrolizumab (us only).

Eligibility criteria:
part 2 (global), part 3 (us only), and part 4 (us only) inclusion criteria: * male or female patients aged \>/=18 years * patients with a histologically or cytologically confirmed solid tumor or aggressive nhl who are refractory to or have exhausted all available therapies with myc expression or known c-myc amplification/alterations * adequate bone marrow, liver, and renal functions * eastern cooperative oncology group (ecog) performance status of 0 to 2 in the addition to the above part 3 (us only) and part 4 (us only) * must be eligible to use pembrolizumab per uspi exclusion criteria: * active clinically serious infections of events \> grade 2 * subjects who have new or progressive brain or meningeal or spinal metastases. * anticancer chemotherapy or immunotherapy during the study or within 1 weeks prior to the first dose of study drug * major surgery or significant trauma within 4 weeks before the first dose of study drug * allogeneic bone marrow transplant or stem cell rescue within 4 months before first dose of study drug; patients must have completed immunosuppressive therapy before enrollment.

Keywords: solid tumors aggressive non-hodgkin's lymphoma (nhl) advanced ovarian cancer triple negative breast cancer dhl double-hit lymphoma transformed follicular lymphoma mantle cell prostate cancer melanoma non-small cell lung cancer head and neck squamous cell cancer esophageal cancer urothelial carcinoma tumor mutational burden-high cancer cutaneous squamous cell carcinoma microsatellite instability-high or mismatch repair deficient cancer microsatellite instability-high or mismatch repair deficient colorectal cancer gastric cancer cervical cancer hepatocellular carcinoma merkel cell carcinoma renal cell carcinoma endometrial carcinoma myc overexpression myc amplification myc translocation classic hodgkins primary mediastinal large b cell lymphoma
desloratadine with oxybutynin for the treatment of seasonal allergic rhinitis and post-nasal drip (study p04258)(completed)

Conditions: Post-nasal Drip; Seasonal Allergic Rhinitis; Rhinorrhea

Summary: this was a 1-week study of desloratadine (dl) plus oxybutynin (oxy) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.


Eligibility criteria:
inclusion criteria: subjects must: * be \>=18 years of age, * be free of any clinically significant disease that would interfere with study, other than seasonal allergic rhinitis (sar), * have a documented diagnosis of sar for \>=2 years, * have had a positive skin-prick test, * be sufficiently symptomatic at the screening visit, * for the 3 calendar days immediately prior to baseline visit, plus the am of the baseline visit, the seven twice-daily run-in diary prior total nasal symptom scores must have totaled \>=42, the total non-nasal symptoms score must have totaled \>=28, and the total post nasal drip score must have totaled \>=14, * be in general good health. exclusion criteria: subjects who have: * certain medical conditions or medical histories, * allergies to any of the components in any of the study medications, * nasal structure abnormalities, * dependency to nasal, oral, or ocular decongestants, nasal topical antihistamines, or nasal steroids, * used any investigational drug use in past 30 days, * received immunotherapy (desensitization) * are pregnant